With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management, announced it has secured an additional $4 million in debt financing from Perceptive Advisors.

In other recent news, Trinity Biotech reported a 3% year-on-year revenue growth in its third quarter of 2024, amounting to $15.2 million. Despite a post-tax net loss of $4.8 million, the company ...

StockNews.com cut shares of Trinity Biotech (NASDAQ:TRIB – Free Report) from a hold rating to a sell rating in a research report released on Thursday. Trinity Biotech Stock Up 1.6 % Shares of TRIB ...

Trinity Biotech projects an annualized run rate of $20 million in EBITDASO and $75 million in revenues by Q2 2025, with a 20% sales increase and a $6.5 million EBITDA turnaround anticipated in 2025.

Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its continuous glucose monitoring system. Trinity Biotech plc (NASDAQ: TRIB ...

Research analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report released on Wednesday. The firm set a “hold” rating on the stock. Trinity ...

Trinity Biotech PLC (TRIB) reports a 3% revenue increase and outlines strategic initiatives for future growth and profitability. Trinity Biotech PLC (TRIB) reports a 14% revenue increase with ...